Developing new drug formulations for clinical trials
Official title: ALBANY MOLECULAR RESEARCH, INC(AMRI)[19-002417]MCSP TASK ORDER XU PROJECT - EXPLORATORY CHEMISTRY POP: TBD
Funded at Albany Molecular Research, INC. · NIH-10031075 · Data updated 2026-11-12
This study is all about creating new medicines that could help patients by making sure they are safe and effective before they are tested in clinical trials.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Albany Molecular Research, INC. NIH-funded |
| Lab location | 1 site (Albany, United States) |
| Project start | March 16, 2018 |
| Project end | March 15, 2028 |
| Funding year | 2019 |
| Award (this year) | $575,359 |
| NIH project number | 271201800001I-0-759501900064-1 |
| Project ID | NIH-10031075 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for participation or benefit are individuals with conditions that could be treated by the new drugs being developed.
✕Less likely to help
Patients who are not affected by the conditions targeted by the new drug formulations may not receive any benefit from this research.
What this research studies
This research focuses on the development and manufacturing of new drug formulations that are suitable for clinical trials. It involves creating small molecule drug candidates and ensuring they meet regulatory standards for safety and efficacy. The process includes various stages such as formulation studies, analytical method development, and compliance with Good Manufacturing Practices (cGMP). Patients may benefit from new medications that emerge from this rigorous development process.
Why it matters
Potential benefit: If successful, this research could lead to the creation of new and effective medications for various conditions.
How similar studies have gone: Previous research within the Blueprint Neurotherapeutics Network has shown success in accelerating drug development processes.
Where this research is happening
-
Albany Molecular Research, INC.
Albany, United States Active
Researchers
- Principal investigator: Allard, Melissa — Albany Molecular Research, INC.
- Study coordinator: Allard, Melissa
Related research
Other NIH-funded projects on the same topics.
-
Accelerating the development of new drugs for neurological conditions
This study is all about finding and creating new medicines for brain-related conditions faster, so that patients can have more treatment options that are safe and effective.
-
Developing new drugs to manage pain and substance use disorders
This study is working on new medications to help people manage pain better and tackle issues with substance use, aiming to create treatments that could improve your quality of life.
-
Improving treatments for antibiotic-resistant bacterial infections
This study is working on creating new treatments for tough infections caused by antibiotic-resistant bacteria, like Acinetobacter and Pseudomonas aeruginosa, to help patients who currently have limited options for effective care.
-
Developing a new treatment for safety evaluation and clinical trials.
This study is working on a new medicine called NCGC00413972 to make sure it’s safe and effective for people, with the hope that it could offer new treatment options in the future.
-
Investigating ways to improve pain management and drug formulation.
This study is all about finding better ways to manage pain by creating new and improved medications, and it’s designed for patients who are looking for effective pain relief options.
-
Developing new treatments for Alzheimer's Disease through medicinal chemistry
This study is exploring new ways to create medications for Alzheimer's Disease that could help patients by targeting the specific processes involved in the condition.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.